Communicating the relevance of neurodegeneration and brain atrophy to multiple sclerosis patients: patient, provider and researcher perspectives

[1]  C. Pozzilli,et al.  Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study , 2021, JAMA neurology.

[2]  A. Brunetti,et al.  Neuroimaging Correlates of Cognitive Dysfunction in Adults with Multiple Sclerosis , 2021, Brain sciences.

[3]  M. Dwyer,et al.  Interpretation of Brain Volume Increase in Multiple Sclerosis , 2020, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[4]  E. Vettorazzi,et al.  Assessing the effect of an evidence-based patient online educational tool for people with multiple sclerosis called UMIMS—understanding magnetic resonance imaging in multiple sclerosis: study protocol for a double-blind, randomized controlled trial , 2020, Trials.

[5]  M. Dwyer,et al.  Slowing of brain atrophy with teriflunomide and delayed conversion to clinically definite MS , 2020, Therapeutic advances in neurological disorders.

[6]  E. Bernitsas,et al.  Approved and Emerging Disease Modifying Therapies on Neurodegeneration in Multiple Sclerosis , 2020, International journal of molecular sciences.

[7]  D. Louis Collins,et al.  Brain volume loss in individuals over time: Source of variance and limits of detectability , 2020, NeuroImage.

[8]  M. Battaglini,et al.  MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice , 2020, Nature Reviews Neurology.

[9]  Jeffrey A. Cohen,et al.  Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial , 2019, The Lancet Neurology.

[10]  Jeffrey A. Cohen,et al.  Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial , 2019, The Lancet Neurology.

[11]  D. Ramasamy,et al.  Atrophied Brain T2 Lesion Volume at MRI Is Associated with Disability Progression and Conversion to Secondary Progressive Multiple Sclerosis. , 2019, Radiology.

[12]  A. Artemiadis,et al.  Brain atrophy in multiple sclerosis: mechanisms, clinical relevance and treatment options , 2019, Autoimmunity Highlights.

[13]  D. Chard,et al.  Emotions towards magnetic resonance imaging in people with multiple sclerosis , 2019, Acta neurologica Scandinavica.

[14]  Eva Kubala Havrdova,et al.  Pathological cut-offs of global and regional brain volume loss in multiple sclerosis , 2019, Multiple sclerosis.

[15]  W. van Hecke,et al.  Comparing longitudinal brain atrophy measurement techniques in a real-world multiple sclerosis clinical practice cohort: towards clinical integration? , 2019, Therapeutic advances in neurological disorders.

[16]  Massimo Filippi,et al.  Urgent challenges in quantification and interpretation of brain grey matter atrophy in individual MS patients using MRI , 2018, NeuroImage: Clinical.

[17]  Ludwig Kappos,et al.  Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study , 2018, The Lancet.

[18]  M. Dwyer,et al.  Establishing pathological cut-offs for lateral ventricular volume expansion rates , 2018, NeuroImage: Clinical.

[19]  D. Pelletier,et al.  Thalamic atrophy in multiple sclerosis: A magnetic resonance imaging marker of neurodegeneration throughout disease , 2018, Annals of neurology.

[20]  Nicholas C. Firth,et al.  Progression of regional grey matter atrophy in multiple sclerosis , 2017, bioRxiv.

[21]  L. Kappos,et al.  Teriflunomide slows BVL in relapsing MS , 2017, Neurology: Neuroimmunology & Neuroinflammation.

[22]  D. Ramasamy,et al.  Neurological software tool for reliable atrophy measurement (NeuroSTREAM) of the lateral ventricles on clinical-quality T2-FLAIR MRI scans in multiple sclerosis , 2017, NeuroImage: Clinical.

[23]  Deborah Pareto,et al.  Brain Atrophy in Multiple Sclerosis: Clinical Relevance and Technical Aspects. , 2017, Neuroimaging clinics of North America.

[24]  M. Battaglini,et al.  Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets , 2017, Multiple sclerosis.

[25]  M. Battaglini,et al.  Brain MRI atrophy quantification in MS , 2017, Neurology.

[26]  Bernhard Hemmer,et al.  Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis , 2017, The New England journal of medicine.

[27]  A. Traboulsee,et al.  Ocrelizumab versus Interferon Beta‐1a in Relapsing Multiple Sclerosis , 2017, The New England journal of medicine.

[28]  L. Jones,et al.  B2 Cell-based assays of CAG repeat instability in the huntingtin (HTT) gene , 2016 .

[29]  D. Pelletier,et al.  Whole-brain atrophy: ready for implementation into clinical decision-making in multiple sclerosis? , 2016, Current opinion in neurology.

[30]  R. Benedict,et al.  Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine , 2016, Expert review of neurotherapeutics.

[31]  S. Hatton,et al.  Automated brain volumetrics in multiple sclerosis: a step closer to clinical application , 2016, Journal of Neurology, Neurosurgery & Psychiatry.

[32]  F. Barkhof,et al.  Multi-parametric structural magnetic resonance imaging in relation to cognitive dysfunction in long-standing multiple sclerosis , 2016, Multiple sclerosis.

[33]  Ludwig Kappos,et al.  Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial , 2016, The Lancet.

[34]  D. Arnold,et al.  Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. , 2015, The New England journal of medicine.

[35]  M. Battaglini,et al.  Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis , 2015, Journal of Neurology, Neurosurgery & Psychiatry.

[36]  David H. Miller,et al.  Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study , 2015, Neurology.

[37]  D. Arnold,et al.  Towards a better understanding of pseudoatrophy in the brain of multiple sclerosis patients , 2015, Multiple sclerosis.

[38]  A. Rahn,et al.  Magnetic Resonance Imaging in Multiple Sclerosis – Patients' Experiences, Information Interests and Responses to an Education Programme , 2014, PloS one.

[39]  Ludwig Kappos,et al.  Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial , 2014, The Lancet Neurology.

[40]  D. Arnold,et al.  Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study , 2014, Journal of Neurology.

[41]  D. Arnold,et al.  Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study , 2014, The Lancet Neurology.

[42]  P. Vermersch,et al.  Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial , 2014, The Lancet Neurology.

[43]  Turi O. Dalaker,et al.  Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[44]  A. Zell,et al.  Correction: Screening for Protein-DNA Interactions by Automatable DNA-Protein Interaction ELISA , 2014, PLoS ONE.

[45]  F. Barkhof,et al.  Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[46]  Sofia Carlsson,et al.  'The situation and the uncertainty about the coming result scared me but interaction with the radiographers helped me through': a qualitative study on patients' experiences of magnetic resonance imaging examinations. , 2013, Journal of clinical nursing.

[47]  R. Zivadinov,et al.  Three times weekly glatiramer acetate in relapsing–remitting multiple sclerosis , 2013, Annals of neurology.

[48]  Christian Confavreux,et al.  Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial , 2012, The Lancet.

[49]  Jeffrey A. Cohen,et al.  Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial , 2012, The Lancet.

[50]  R. Kahn,et al.  Human brain changes across the life span: A review of 56 longitudinal magnetic resonance imaging studies , 2012, Human brain mapping.

[51]  M. Sormani,et al.  Efficacy and safety of subcutaneous interferon beta-1a in relapsing–remitting multiple sclerosis: Further outcomes from the IMPROVE study , 2012, Journal of the Neurological Sciences.

[52]  Christian Confavreux,et al.  Randomized trial of oral teriflunomide for relapsing multiple sclerosis. , 2011, The New England journal of medicine.

[53]  Z. Munn,et al.  The patient experience of high technology medical imaging: a systematic review of the qualitative evidence , 2011, JBI library of systematic reviews.

[54]  P. Calabresi,et al.  Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis , 2010, Journal of the Neurological Sciences.

[55]  Ludwig Kappos,et al.  A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. , 2010, The New England journal of medicine.

[56]  Ludwig Kappos,et al.  Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. , 2010, The New England journal of medicine.

[57]  F Fazekas,et al.  Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial , 2009, The Lancet.

[58]  M. Filippi,et al.  250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study , 2009, The Lancet Neurology.

[59]  M. Filippi,et al.  Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis , 2008, Neurology.

[60]  M. Rovaris,et al.  Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial , 2007, Multiple sclerosis.

[61]  M. Schocke,et al.  A widespread distinct pattern of cerebral atrophy in patients with alcohol addiction revealed by voxel-based morphometry , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[62]  Rohit Bakshi,et al.  The measurement and clinical relevance of brain atrophy in multiple sclerosis , 2006, The Lancet Neurology.

[63]  Marco Rovaris,et al.  Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial , 2004, The Lancet.

[64]  Stephen M. Smith,et al.  Accurate, Robust, and Automated Longitudinal and Cross-Sectional Brain Change Analysis , 2002, NeuroImage.

[65]  David H. Miller,et al.  Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. , 2002, Brain : a journal of neurology.

[66]  A. Dale,et al.  Whole Brain Segmentation Automated Labeling of Neuroanatomical Structures in the Human Brain , 2002, Neuron.

[67]  Ponnada A Narayana,et al.  United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates , 2001 .

[68]  J S Wolinsky,et al.  United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center. , 2001, Multiple sclerosis.

[69]  J. Duda,et al.  Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon β-1a , 2000, Multiple sclerosis.

[70]  C. Boz,et al.  Evaluating Treatment Decision for Multiple Sclerosis: Real Life and Patient Experiences. , 2018, Noro psikiyatri arsivi.

[71]  O. Khan,et al.  Spinal cord atrophy in multiple sclerosis and relationship with disability across clinical phenotypes. , 2015, Multiple sclerosis and related disorders.